Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Prashant K. Singh
Institution:
Roswell Park Comprehensive Cancer Center
Observed institution:
Roswell Park Comprehensive Cancer Center
ORCID:
0000-0001-5649-8424
Observed ORCID:
0000-0001-5649-8424
OpenAlex ID:
A5139919120
Tumor-Derived Complement C3 Overexpression in STK11 -Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
·
Cancer Immunology Research
·
3
Figure S5 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
Table S1 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
Figure S2 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
Figure S3 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
Figure S10 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
Table S2 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
Figure S8 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
Figure S7 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
Data from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
Figure S4 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
Figure S1 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
Figure S6 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
Figure S9 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
Table S3 from Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance
2026
·
Sora Suzuki
, Bojidar Kandar
, et al.
Show more works
View as search
Works count:
15
Citation count:
3
H-index:
1
I10-index:
Year
Topic
Type